van der Straten L, Stege CAM, Kersting S, et al. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL. Blood. 2023;142(13):1131-1142.

There are errors in the supplemental file. The list of members of the HOVON CLL working group is incomplete. Also, under “Minimal important differences,” the sentence “More specifically, distribution-based MIDs were calculated as 0.5 times the standard deviation (SD) for single-scale items and as the baseline mean QoL score times the square root of (1-Cronbach’s α)” should read “More specifically, distribution-based MIDs were calculated as 0.5 times the standard deviation (SD) for single-scale items and as the SD of the baseline mean QoL score times the square root of (1-Cronbach’s α).” The corrected supplemental file is available in the HTML version of this erratum.